Canada: British Columbia Legislative Update In Health Law

A look at five recently introduced pieces of health legislation in B.C. and their anticipated effects on health care providers and patients.

Spring 2012 has seen the introduction of several new pieces of legislation in the Provincial Legislature specifically directed to the health care field. This new legislation includes:

  • Bill 35 - The Pharmaceutical Services Act
  • Bill 39 - The Emergency Intervention Disclosure Act
  • Bill 48 - The Emergency Health Services Amendment Act
  • Bill 41 - The Miscellaneous Statutes Amendment Act
  • Bill 34 - Limitation Act

The following material highlights the significant sections of each statute. If you have any questions about any of this new legislation.


On April 24, 2012, the Provincial Government introduced the Pharmaceutical Services Act ("PSA" or the "Act"), which came into force on May 31, 2012. The new PSA gives legislative recognition to the Pharmacare Program, which is a government funded drug program introduced in British Columbia in the 1970's and which has, until now, only existed within government policy documents, manuals and through a patchwork of references in various health-related statutes. British Columbia's historical treatment of the Pharmacare drug program has been unlike other jurisdictions in Canada where such drug programs have typically been entrenched through legislation.

The PSA is primarily directed to three purposes:

  • entrenching the principles and processes applicable to the existing Pharmacare program,
  • empowering the Province with new statutory authority to lower generic drug prices in an effort to secure savings and support the sustainability of Pharmacare, and
  • providing new rules regarding use, collection and disclosure of personal information collected in connection to Pharmacare and other pharmaceutical record-keeping systems.


Legislated Recognition of Provincial Drug Programs (Pharmacare)

At the time of its creation, Pharmacare was established to provide financial assistance to B.C. residents for the purchase of prescription drugs and other medical supplies. The Program now offers financial assistance through several separate drug plans, including Fair Pharmacare, which offers funding assistance based on income to all residents of B.C. registered with MSP, and other directed programs which are available to prescribed categories of persons. The PSA has the effect of continuing Pharmacare, but, like other jurisdictions in Canada, it will now do so through a legislated structure which involves:

  • Creation of Provincial Drug Program, including the promulgation of public lists and formularies for each plan that is established.
  • Beneficiary Enrolment and Eligibility, which requires beneficiary registration and empowers the government to establish specific terms and conditions of participation and eligibility.
  • Provider and Practitioner Enrolment, which requires pharmacies and other providers and participating practitioners to enrol and empowers government to establish specific terms and conditions of participation and eligibility.
  • Ensuring that Pharmacare is an Insurance of "Last Resort", continuing a principle under the existing Pharmacare program that benefits are not available from a government funded drug program where the beneficiary is entitled to receive them through another funded source.

Controls on Drug Pricing and Marketing Practices

  • Price Regulation - One of the most significant aspects of the Act is that it empowers the Province to set limits and conditions on the amount that will be paid by the government for a particular drug, device, substance or service that is a benefit under this legislation. The details of how this power would be applied and administered are anticipated to be provided subsequently by regulation.
  • Prohibition or Limitation on Use of Incentives - The Act empowers the provincial government to limit or prohibit the use by manufacturers of generic drugs of discounts, rebates or other incentives to pharmacies and other drug providers in an effort to support competitive pricing for British Columbians. The Act imposes obligations on providers and others to report the receipt of any such incentives.

Personal Information Management and Administration

The PSA also addresses the collection, use and disclosure of personal information in connection with individual drug and prescription histories. The PSA seeks both to authorize the Province's use of such information for health care and other purposes and to incorporate controls to address potential privacy violations and the misuse of such information.

  • Authorized Uses of Prescription History and Usage - Notably, the Act provides the Province with some expansive powers to use personal information collected under this legislation for broader purposes than simply health care and treatment, including health insurance and billing, health system planning, research, public health and other purposes to be prescribed by regulation.
  • Privacy Protections - The PSA also seeks to impose limits and privacy protections on the use of personal information collected under this legislation, including by prohibiting secondary disclosure of data by recipients, prohibiting its use for market research, requiring that researchers make formal application to a Data Stewardship Committee for access to such data and providing individuals with some limited controls over how their own information can be controlled and used.
  • PharmaNet and Other "Prescribed Information Management Technology" - The PSA also recognizes and seeks to regulate existing and future pharmaceutical information banks, including those currently maintained through the PharmaNet system. PharmaNet is a province-wide system that links all B.C. pharmacies and, among other things, contains information about individual drug prescription histories. It allows the Province, health care providers and drug providers to identify duplicated prescriptions, provide health care, identify drug interactions, and prevent fraud and adjudicate claims under Pharmacare. The PSA seeks to establish legislated limits and conditions on who may access these systems, the ability of individuals to limit access to their own information (through the use of a keyword or protective word) and authorizes the government to enact further regulations regarding access, use and conditions applicable to these information management systems.


The Emergency Intervention Disclosure Act which passed third reading and received Royal Assent on May 31, 2012, is directed to the protection of emergency and health care workers who are at risk of occupational exposure to communicable diseases, such as HIV, Hepatitis B and C. This Act allows any such workers who may have been exposed to a communicable disease through contact with the bodily substances of another person (referred to as the "source individual") to seek a court order compelling the source individual to undergo testing for communicable disease.

Those that may apply for testing include any persons who may be exposed to contaminants while providing emergency medical services or while performing their duties as firefighters, as emergency medical assistants or as peace officers. The Act also leaves open the possibility for other circumstances or professions to be included in this legislation by regulation.

Before granting a testing order, the court must be satisfied of a number of factors, perhaps most prominently that there are reasonable grounds to believe the applicant may have been exposed to a prescribed pathogen, and that testing the applicant is not a viable option insofar as it would not yield results within a timely manner.

This new legislation has been the subject of some criticism on the basis that it is overly invasive of the privacy interests of the source individual. The Act does include some measures designed to protect the interests of the source individual, such as by requiring that court applications be supported by a physician's report, and that prior notice of the application be given to the individual, if possible or practicable. Any order, if made, will also be subject to restrictions on testing, how the sample may be used and providing for the confidentiality of the results (subject to circumstances in which disclosure is required by law).

Any source individual who contravenes a testing order commits an offence and is liable to conviction on a fine of not more than $10,000. Contravention of the confidentiality provisions is also an offence and can lead to fines of up to $10,000 for an individual or $25,000 for a corporation.


Bill 48, the Emergency Health Services Amendment Act ("Bill 48") was introduced for first reading on May 7, 2012, and has not yet proceeded to second reading or been passed into law. If passed, this legislation seeks to repeal and replace the current Emergency and Health Services Act.

While Bill 48 seeks to continue the existing Emergency Health Services Commission which is currently responsible for, among other things, urgent care and ambulance services, it provides more detailed provisions concerning the composition and statutory mandate, authority, duties and responsibilities of the Commission. It also includes new provisions that would require the Commission to consult with the Provincial Health Services Authority and the other regional health authorities to coordinate the delivery of emergency and urgent health services, ambulance services and other ancillary services.

In introducing the Bill, Health Minister Mike de Jong described the purpose of this Bill as seeking to integrate and coordinate the delivery of ambulance and emergency services in British Columbia more closely with the broader health care system. He also explained that the Bill seeks to more closely align the services provided by the Commission with those provided by the Provincial Health Services Authority, which already has primary responsibility for a number of significant health services and programs that are operated and administered on a province-wide basis.


Bill 41, the Miscellaneous Statutes Amendment Act (#2) was introduced in the legislature on May 1, 2012 and received Royal Assent on May 31, 2012. Among other things, this Bill introduces minor amendments to the Health Professions Act and the Labour Mobility Act which exclude the occupation of nurse practitioners from the application of the Labour Mobility Act. The Labour Mobility Act is legislation that is designed to facilitate the practice of certain occupations or professions within B.C. by qualified individuals from other Canadian jurisdictions without requiring such individuals to undergo additional testing or certification requirements. The exclusion of nurse practitioners from this legislation means that nurse practitioners from other Canadian jurisdictions who seek to practice in B.C. will be subject to the same testing and certification requirements as are applicable to other nurse practitioners in British Columbia.


While not yet in force, Bill 34, the Limitation Act was introduced in the legislature on April 17, 2012 (and received Royal Assent May 14, 2012) as a fundamental reform of the Province's existing Limitation Act. The new legislation seeks to bring British Columbia's rules regarding limitation periods for commencing legal action into harmony with the rules existing in a number of other Canadian jurisdictions.

Some of the changes introduced under the new Limitation Act include:

  • Where the former Limitation Act established an array of limitation periods ranging from two years to ten years for differing types of legal claims, the new Limitation Act provides for a single basic limitation period of two years for most civil claims falling within the scope of the Act.
  • Unlike the former Act, the new legislation will postpone the running of time for the ultimate limitation as well as the basic limitation during a period of adult disability.
  • Under the new legislation, civil claims will still be subject to a principle known as "discoverability," which holds that a limitation period only begins to run from the time that the claimant knew or ought reasonably to have known of the existence of a claim. The new legislation, like the existing Act, also sets out other circumstances in which limitation periods may be postponed. However, whereas most such postponed claims were still previously subject to a 30-year ultimate limitation period regardless of the discoverability principle or any other statutory postponement of the period, the new legislation reduces the ultimate limitation period to 15 years, subject to certain exceptions (such as circumstances where the claimant was wilfully misled or relevant facts were wilfully concealed by the prospective defendant).
  • The new legislation is important for Health Care because it will have the effect of repealing a provision in the existing Limitation Act which provides that claims against a hospital, a hospital employee or physician for professional negligence or medical malpractice are subject to an ultimate limitation period of six years, regardless of discoverability or any statutory postponement of the running of time.

For most of the Province, the introduction of the new Limitation Act can be expected to have the effect of providing greater certainty and, by virtue of the shortened limitation periods, an overall reduction in exposure to legal claims. The effect of this legislation to professionals in the health care field will, however, necessarily be more varied in nature, and, in particular, the following impacts on the health care field are of note:

  • The new basic limitation period of two years (reduced from six) will reduce exposure to certain types of claims, such as those based upon breaches of fiduciary duty, wrongful dismissal and breach of contract.
  • The repeal of the ultimate limitation period of six years for hospitals, hospital employees and medical practitioners, and its replacement with an ultimate limitation period of 15 years will increase exposure for some health care bodies and professionals.
  • Likewise, the introduction of provisions postponing not just the basic limitation but also the ultimate limitation for adults under a disability may increase overall legal exposure for those working in the health care field.

Bill 34 has passed third reading and has received Royal Assent. The government has yet to announce when it is expected to be brought into force.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions